5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity

Leukemia

Volumn 26, Issue 8, 2012, Pages 1804-1811

  Curik, N ^a   Burda, P ^a   Vargova, K ^a   Pospisil, V ^a   Belickova, M ^b   Vlckova, P ^a   Savvulidi, F ^a   Necas, E ^a   Hajkova, H ^b   Haskovec, C ^b   Cermak, J ^b   Krivjanska, M ^c   Trneny, M ^a,b,d   Laslo, P ^e   Jonasova, A ^a,d   Stopka, T ^a,d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^c KRD and CEBIOS   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

5 azacitidine; AML; cytokines; differentiation; MDS; PU.1

Indexed keywords

AZACITIDINE; CD34 ANTIGEN; COLONY STIMULATING FACTOR; DNA; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE; TRANSCRIPTION FACTOR PU 1;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CHROMATIN STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; IN VITRO STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REGULATORY SEQUENCE; UPREGULATION; UPSTREAM REGULATORY ELEMENT;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHROMATIN; COLONY-STIMULATING FACTORS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS; REGULATORY SEQUENCES, NUCLEIC ACID; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84864869497     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.47     Document Type: Article

References (44)

1. Laslo P, Spooner CJ, Warmflash A, Lancki DW, Lee HJ, Sciammas R et al. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell 2006; 126: 755-766.
2. Dahl R, Simon MC. The importance of PU.1 concentration in hematopoietic lineage commitment and maturation. Blood Cells Mol Dis 2003; 31: 229-233.
3. Stopka T, Amanatullah DF, Papetti M, Skoultchi AI. PU.1 inhibits the erythroid program by binding to GATA-1 on DNA and creating a repressive chromatin structure. EMBO J 2005; 24: 3712-3723.
4. Burda P, Curik N, Kokavec J, Basova P, Mikulenkova D, Skoultchi AI et al. PU.1 activation relieves GATA-1-mediated repression of Cebpa and Cbfb during leukemia differentiation. Mol Cancer Res 2009; 7: 1693-1703.
5. Ross IL, Yue X, Ostrowski MC, Hume DA. Interaction between PU.1 and another Ets family transcription factor promotes macrophage-specific Basal transcription initiation. J Biol Chem 1998; 273: 6662-6669.
6. Yamamoto H, Kihara-Negishi F, Yamada T, Hashimoto Y, Oikawa T. Physical and functional interactions between the transcription factor PU.1 and the coactivator CBP. Oncogene 1999; 18: 1495-1501.
7. Hoogenkamp M, Krysinska H, Ingram R, Huang G, Barlow R, Clarke D et al. The Pu.1 locus is differentially regulated at the level of chromatin structure and noncoding transcription by alternate mechanisms at distinct developmental stages of hematopoiesis. Mol Cell Biol 2007; 27: 7425-7438.
8. Petrovick MS, Hiebert SW, Friedman AD, Hetherington CJ, Tenen DG, Zhang DE. Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1. Mol Cell Biol 1998; 18: 3915-3925.
9. Wontakal SN, Guo X, Will B, Shi M, Raha D, Mahajan MC et al. A large gene network in immature erythroid cells is controlled by the myeloid and B cell transcriptional regulator PU.1. PLoS Genet 2011; 7: e1001392.
10. Okuno Y, Huang G, Rosenbauer F, Evans EK, Radomska HS, Iwasaki H et al. Potential autoregulation of transcription factor PU.1 by an upstream regulatory element. Mol Cell Biol 2005; 25: 2832-2845.
11. Chen H, Ray-Gallet D, Zhang P, Hetherington CJ, Gonzalez DA, Zhang DE et al. PU.1 (Spi-1) autoregulates its expression in myeloid cells. Oncogene 1995; 11: 1549-1560.
12. Rosenbauer F, Wagner K, Kutok JL, Iwasaki H, Le Beau MM, Okuno Y et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 2004; 36: 624-630.
13. Steidl U, Steidl C, Ebralidze A, Chapuy B, Han HJ, Will B et al. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest 2007; 117: 2611-2620.
14. Leddin M, Perrod C, Hoogenkamp M, Ghani S, Assi S, Heinz S et al. Two distinct auto-regulatory loops operate at the PU.1 locus in B cells and myeloid cells. Blood 2011; 117: 2827-2838.
15. Cook WD, McCaw BJ, Herring C, John DL, Foote SJ, Nutt SL et al. PU.1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain. Blood 2004; 104: 3437-3444.
16. Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 2002; 100: 998-1007.
17. Lamandin C, Sagot C, Roumier C, Lepelley P, De Botton S, Cosson A et al. Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)? Blood 2002; 100: 4680-4681.
18. Vegesna V, Takeuchi S, Hofmann WK, Ikezoe T, Tavor S, Krug U et al. C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. Leuk Res 2002; 26: 451-457.
19. Rekhtman N, Radparvar F, Evans T, Skoultchi AI. Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. Genes Dev 1999; 13: 1398-1411.
20. Nerlov C, Querfurth E, Kulessa H, Graf T. GATA-1 interacts with the myeloid PU.1 transcription factor and represses PU.1-dependent transcription. Blood 2000; 95: 2543-2551.
21. Zhang P, Zhang X, Iwama A, Yu C, Smith KA, Mueller BU et al. PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding. Blood 2000; 96: 2641-2648.
22. Moreau-Gachelin F, Tavitian A, Tambourin P. Spi-1 is a putative oncogene in virally induced murine erythroleukaemias. Nature 1988; 331: 277-280.
23. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008; 205: 585-594.
24. Durual S, Rideau A, Ruault-Jungblut S, Cossali D, Beris P, Piguet V et al. Lentiviral PU.1 overexpression restores differentiation in myeloid leukemic blasts. Leukemia 2007; 21: 1050-1059.
25. Tatetsu H, Ueno S, Hata H, Yamada Y, Takeya M, Mitsuya H et al. Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. Cancer Res 2007; 67: 5328-5336.
26. Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N et al. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood 2006; 107: 3330-3338.
27. Gu ZM, Liu CX, Wu SF, Zhao M, Xu HZ, Liu W et al. PU.1 directly regulates retinoic acid-induced expression of RIG-G in leukemia cells. FEBS Lett 2010; 585: 375-380.
28. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895-3903.
29. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
30. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440.
31. Fenaux P, Gattermann N, Seymour JF, Hellstrom-Lindberg E, Mufti GJ, Duehrsen U et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol 2010; 149: 244-249.
32. Fenaux P, Bowen D, Gattermann N, Hellstrom-Lindberg E, Hofmann WK, Pfeilstocker M et al. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. Leuk Res 2010; 34: 1410-1416.
33. Quintas-Cardama A, Santos FP, Garcia-Manero G. Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol 2010; 7: 433-444.
34. Komashko VM, Farnham PJ. 5-Azacytidine treatment reorganizes genomic histone modification patterns. Epigenetics 2010; 5: 229-240.
35. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439: 871-874.
36. Hernandez-Munoz I, Taghavi P, Kuijl C, Neefjes J, van Lohuizen M. Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1. Mol Cell Biol 2005; 25: 11047-11058.
37. Li H, Rauch T, Chen ZX, Szabo PE, Riggs AD, Pfeifer GP. The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. J Biol Chem 2006; 281: 19489-19500.
38. Smallwood A, Esteve PO, Pradhan S, Carey M. Functional cooperation between HP1 and DNMT1 mediates gene silencing. Genes Dev 2007; 21: 1169-1178.
39. Jiemjit A, Fandy TE, Carraway H, Bailey KA, Baylin S, Herman JG et al. p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene 2008; 27: 3615-3623.
40. Hu Z, Negrotto S, Gu X, Mahfouz R, Ng KP, Ebrahem Q et al. Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus. Mol Cancer Ther 2010; 9: 1536-1543.
41. Drexler HG, Dirks WG, Macleod RA. Many are called MDS cell lines: one is chosen. Leuk Res 2009; 33: 1011-1016.
42. Si J, Boumber YA, Shu J, Qin T, Ahmed S, He R et al. Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. Cancer Res 2010; 70: 6968-6977.
43. Dotti G, Stella CC, Mangoni L, Cottafavi L, Caramatti C, Almici C et al. Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy. Haematologica 1995; 80: 142-145.
44. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12: 671-678.